MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Prior treatment

• History of active malignancy within 3 years prior to screening
• RNA silencer therapy (patisiran, inotersen and/or eplontersen) within 12 months prior to dosing. Any prior vutrisiran use is not allowed
• Initiation of tafamidis or acoramidis within 56 days prior to study dosing

Other illness

• New York Heart Association (NYHA) Class IV HF
• Has hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
• History of liver disease

Lab values

• Estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73m\^2

Other

• Polyneuropathy Disability score of IV (confined to wheelchair or bed)
• Uncontrolled blood pressure
• Unable or unwilling to take vitamin A supplementation for the duration of the study

• Documented diagnosis of ATTR amyloidosis with cardiomyopathy
• Medical history of heart failure (HF)
• Symptoms of HF are optimally managed and clinically stable within 28 days prior to administration of study intervention
• Screening NT-proBNP, a blood marker of HF severity, greater than or equal to 600 pg/mL and less than 10,000 pg/mL